Detalhe da pesquisa
1.
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.
Ann Oncol
; 34(3): 262-274, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36535565
2.
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
Ann Oncol
; 32(5): 609-619, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33610734
3.
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.
Ann Oncol
; 31(7): 942-950, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32294530
4.
Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study.
Lung Cancer
; 77(2): 376-82, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22498112